Literature DB >> 27532916

Association of Noninvasive Ventilation Strategies With Mortality and Bronchopulmonary Dysplasia Among Preterm Infants: A Systematic Review and Meta-analysis.

Tetsuya Isayama1, Hiroko Iwami2, Sarah McDonald3, Joseph Beyene4.   

Abstract

IMPORTANCE: Various noninvasive ventilation strategies are used to prevent bronchopulmonary dysplasia (BPD) of preterm infants; however, the best mode is uncertain.
OBJECTIVE: To compare 7 ventilation strategies for preterm infants including nasal continuous positive airway pressure (CPAP) alone, intubation and surfactant administration followed by immediate extubation (INSURE), less invasive surfactant administration (LISA), noninvasive intermittent positive pressure ventilation, nebulized surfactant administration, surfactant administration via laryngeal mask airway, and mechanical ventilation. DATA SOURCES: MEDLINE, EMBASE, CINAHL, and Cochrane CENTRAL from their inceptions to June 2016. STUDY SELECTION: Randomized clinical trials comparing ventilation strategies for infants younger than 33 weeks' gestational age within 24 hours of birth who had not been intubated. DATA EXTRACTION AND SYNTHESIS: Data were independently extracted by 2 reviewers and synthesized with Bayesian random-effects network meta-analyses. MAIN OUTCOMES AND MEASURES: A composite of death or BPD at 36 weeks' postmenstrual age was the primary outcome. Death, BPD, severe intraventricular hemorrhage, and air leak by discharge were the main secondary outcomes.
RESULTS: Among 5598 infants involved in 30 trials, the incidence of the primary outcome was 33% (1665 of 4987; including 505 deaths and 1160 cases of BPD). The secondary outcomes ranged from 6% (314 of 5587) for air leak to 26% (1160 of 4455) for BPD . Compared with mechanical ventilation, LISA had a lower odds of the primary outcome (odds ratio [OR], 0.49; 95% credible interval [CrI], 0.30-0.79; absolute risk difference [RD], 164 fewer per 1000 infants; 57-253 fewer per 1000 infants; moderate quality of evidence), BPD(OR, 0.53; 95% CrI, 0.27-0.96; absolute RD, 133 fewer per 1000 infants; 95% CrI, 9-234 fewer per 1000 infants; moderate-quality), and severe intraventricular hemorrhage (OR, 0.44; 95% CrI, 0.19-0.99; absolute RD, 58 fewer per 1000 births; 95% CrI, 1-86 fewer per 1000 births; moderate-quality). Compared with nasal CPAP alone, LISA had a lower odds of the primary outcome (OR, 0.58; 95% CrI, 0.35-0.93; absolute RD, 112 fewer per 1000 births; 95% CrI, 16-190 fewer per 1000 births; moderate quality), and air leak (OR, 0.24; 95% CrI, 0.05-0.96; absolute RD, 47 fewer per 1000 births; 95% CrI, 2-59 fewer per 1000 births; very low quality). Ranking probabilities indicated that LISA was the best strategy with a surface under the cumulative ranking curve of 0.85 to 0.94, but this finding was not robust for death when limited to higher-quality evidence. CONCLUSIONS AND RELEVANCE: Among preterm infants, the use of LISA was associated with the lowest likelihood of the composite outcome of death or BPD at 36 weeks' postmenstrual age. These findings were limited by the overall low quality of evidence and lack of robustness in higher-quality trials.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27532916     DOI: 10.1001/jama.2016.10708

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  59 in total

1.  Prevention of bronchopulmonary dysplasia: current strategies.

Authors:  Deepak Jain; Eduardo Bancalari
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-08

2.  Predictors of length of stay for initial hospitalization in infants with bronchopulmonary dysplasia.

Authors:  Christopher B Morrow; Sharon A McGrath-Morrow; Joseph M Collaco
Journal:  J Perinatol       Date:  2018-06-08       Impact factor: 2.521

3.  Surfactant utilization and short-term outcomes in an era of non-invasive respiratory support in Canadian neonatal intensive care units.

Authors:  K Raghuram; A Mukerji; J Young; W Yee; M Seshia; K Dow; V Shah
Journal:  J Perinatol       Date:  2017-06-29       Impact factor: 2.521

Review 4.  Surfactant for Respiratory Distress Syndrome: New Ideas on a Familiar Drug with Innovative Applications.

Authors:  H J Niemarkt; M C Hütten; Boris W Kramer
Journal:  Neonatology       Date:  2017-05-25       Impact factor: 4.035

Review 5.  Optimizing respiratory management in preterm infants: a review of adjuvant pharmacotherapies.

Authors:  Jenny K Koo; Robin Steinhorn; Anup C Katheria
Journal:  J Perinatol       Date:  2021-07-09       Impact factor: 2.521

6.  Treatment and outcome data of very low birth weight infants treated with less invasive surfactant administration in comparison to intubation and mechanical ventilation in the clinical setting of a cross-sectional observational multicenter study.

Authors:  Kristina Langhammer; Bernhard Roth; Angela Kribs; Wolfgang Göpel; Ludwig Kuntz; Felix Miedaner
Journal:  Eur J Pediatr       Date:  2018-05-28       Impact factor: 3.183

Review 7.  The clinical management and outcomes of extremely preterm infants in Japan: past, present, and future.

Authors:  Tetsuya Isayama
Journal:  Transl Pediatr       Date:  2019-07

8.  Bronchopulmonary Dysplasia: Executive Summary of a Workshop.

Authors:  Rosemary D Higgins; Alan H Jobe; Marion Koso-Thomas; Eduardo Bancalari; Rose M Viscardi; Tina V Hartert; Rita M Ryan; Suhas G Kallapur; Robin H Steinhorn; Girija G Konduri; Stephanie D Davis; Bernard Thebaud; Ronald I Clyman; Joseph M Collaco; Camilia R Martin; Jason C Woods; Neil N Finer; Tonse N K Raju
Journal:  J Pediatr       Date:  2018-03-16       Impact factor: 4.406

9.  European perspective on less invasive surfactant administration-a survey.

Authors:  Daniel Klotz; Ugo Porcaro; Thilo Fleck; Hans Fuchs
Journal:  Eur J Pediatr       Date:  2016-12-09       Impact factor: 3.183

Review 10.  Surfactant instillation in spontaneously breathing preterm infants: a systematic review and meta-analysis.

Authors:  Vincent Rigo; Caroline Lefebvre; Isabelle Broux
Journal:  Eur J Pediatr       Date:  2016-09-27       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.